Stoke Therapeutics Inc share price logo

Stoke Therapeutics Inc Share Price

NASDAQ: STOK

Mid Cap

$34.93

-0.97

(-2.70%)

as on

Stoke Therapeutics Inc Stock Performance

as on April 24, 2026 at 2:37 pm IST

  • Day's Low

    Day's High

    $34.64
    $37.00
    downward going graph

    0.83%

    Downside

    5.93%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $8.30
    $40.22
    downward going graph

    76.24%

    Downside

    15.14%

    Upside

    downward going graph

Stoke Therapeutics Inc share price movements today

Previous Close
$35.90
Open
$36.31
Volume
348.0K
Day's Low - High
$34.64 - $37.00
52 Week Low - High
$8.30 - $40.22

Stoke Therapeutics Inc Historical Returns

1 Month Return
+ 7.49 %
3 Month Return
+ 21.86 %
1 Year Return
+ 277.1 %
3 Year Return
+ 313.59 %
5 Year Return
+ 13.68 %

Stoke Therapeutics Inc Stock Fundamentals & Key Indicators

Check Stoke Therapeutics Inc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$2.1B

EPS (TTM)

-3.368

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

0

PEG Ratio

0

EBITDA

-18.8M

Revenue (TTM)

184.4M

Profit Margin

-3.73%

Return On Equity TTM

-2.37%

Stoke Therapeutics Inc vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Stoke Therapeutics Inc with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
BUY$2.1B13.68%NA-3.73%
BUY$41.2B127.17%131.818.45%
BUY$111.1B100.86%28.532.94%
NA$34.7BNA126.485.37%
BUY$79.0B52.79%18.0231.41%

Stock Returns calculator for Stoke Therapeutics Inc Stock including INR - Dollar returns

The Stoke Therapeutics Inc stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

Stoke Therapeutics Inc investment value today

Current value as on today

₹4,04,463

Returns

₹3,04,463

(+304.46%)

Returns from Stoke Therapeutics Inc Stock

₹2,66,912 (+266.91%)

Dollar Impact

₹37,551 (+37.55%)

Analyst Recommendation on Stoke Therapeutics Inc Stock

Based on 15 analysts

BUY

86.67%

Buy

13.33%

Hold

0.00%

Sell

Based on 15 analysts, 86.67% of analysts recommend a 'BUY' rating for Stoke Therapeutics Inc. Average target price of $45.1

Stoke Therapeutics Inc Share Price Target

Get share price movements and forecasts by analysts on Stoke Therapeutics Inc.

What analysts predicted

22.55%UPSIDE

Target Price

$45.1

Current Price

$34.93

Analyzed by

15 Analysts

Target

$45.10

Stoke Therapeutics Inc target price $45.1, a slight upside of 22.55% compared to current price of $34.93. According to 15 analysts rating.

Stoke Therapeutics Inc Stock’s Investor Sentiment and Interest

Search interest for Stoke Therapeutics Inc Stock has decreased by -64% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-64% versus previous 30 day period

Stoke Therapeutics Inc Quarterly Profit & Loss

All numbers in Millions USD

Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Total Revenue
3
2
4
4
4
22
158
13
10
1
Gross Profit
2
1
3
3
4
22
158
13
9
0
Operating Income
-27
-29
-28
-29
-30
-13
111
-27
-43
-61
EBITDA
-23
-28
-27
-28
-29
-13
111
-26
-38
-60
Interest Expense
2
2
2
3
3
-
2
0
0
0
Depreciation
0
0
0
0
0
0
0
0
0
0
Income Before Tax
-24
-26
-26
-25
-26
-10
114
-23
-39
-57
Income Tax Expense
-3
10
1
-
-1
-
1
-
-1
-
Net Income
-24
-26
-26
-25
-26
-10
112
-23
-38
-57
Net Profit Margin
-741.90%
-962.10%
-625.57%
-531.88%
-540.05%
-46.35%
71.19%
-169.96%
-360.68%
-4132.24%

Stoke Therapeutics Inc Annual Profit & Loss

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
-
-
-
-
3
12
8
36
184
Gross Profit
0
0
0
-1
-2
12
8
36
184
Operating Income
-5
-12
-35
-53
-86
-104
-114
-101
-20
EBITDA
-5
-12
-35
-52
-85
-102
-112
-99
-18
Interest Expense
-
-
-
-
0
3
9
12
13
Depreciation
0
0
0
0
0
1
2
2
1
Income Before Tax
-5
-12
-32
-52
-85
-101
-104
-88
-6
Income Tax Expense
-
0
-3
-1
-1
-7
4
-88
-
Net Income
-5
-12
-28
-50
-84
-93
-104
-88
-6
Net Profit Margin
0.00%
0.00%
0.00%
0.00%
-2823.70%
-750.58%
-1192.47%
-243.42%
-3.73%

Stoke Therapeutics Inc Quarterly Cash Flow

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Net Income
-26
-26
-25
-26
-10
112
-23
-38
-57
Operating Cash Flow
-20
-24
-17
-21
-23
131
-25
-30
-30
Investing Cash Flow
14
9
-88
-30
0
13
-148
9
-61
Financing Cash Flow
7
1
120
8
0
1
0
3
92
Change in Cash
1
-12
14
-43
-21
146
-173
-18
0

Stoke Therapeutics Inc Annual Cash Flow

All numbers in Millions USD

Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-12
-32
-52
-85
-101
-104
-88
-6
Operating Cash Flow
-10
-31
-42
-66
-31
-81
-86
45
Investing Cash Flow
0
-1
-1
-76
-45
105
-107
-186
Financing Cash Flow
115
149
108
1
46
53
131
97
Change in Cash
103
117
64
-142
-31
77
-63
-43

Global Institutional Holdings in Stoke Therapeutics Inc

Funds
Holdings
Point72 Asset Management, L.P.
2.07%
Dimensional Fund Advisors, Inc.
1.23%
Geode Capital Management, LLC
1.97%
Bank of America Corp
1%
RTW INVESTMENTS, LLC
9.38%

Stoke Therapeutics Inc News & Key Events

  • img

    Today's Timeline - 06 October

    Mon, 05:37 PM

    -

    Stoke Therapeutics appoints Ian F. Smith as permanent CEO, effective October 6, 2025, emphasizing leadership stability and growth.

Insights on Stoke Therapeutics Inc

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Best in 3 Years

    img

    In the last 3 years, STOK has outperformed top 5 stocks with highest market-cap in its industry

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 1 year, STOK stock has moved up by 263.4%

  • imgPOSITIVE IMPACT

    Best in 1 Year

    img

    In the last 1 year, STOK has outperformed top 5 stocks with highest market-cap in its industry

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 4 quarters, 112.87M → -57.93M (in $), with an average decrease of 78.4% per quarter

  • imgNEGATIVE IMPACT

    Revenue Fall

    img

    Revenue is down for the last 4 quarters, 158.56M → 1.40M (in $), with an average decrease of 67.1% per quarter

About Stoke Therapeutics Inc

Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its lead product candidates include STK-002, which is in Phase 1 clinical trials for the treatment of autosomal dominant optic atrophy; and Zorevunersen (STK-001), an investigational new medicine for the treatment of Dravet syndrome is being evaluated in phase 3 clinical trials. The company also develops programs focused on various targets, including haploinsufficiency diseases of the central nervous system and eye. It has a license and collaboration with Biogen Inc. for the development and commercialization of zorevunersen medicine for the treatment of Dravet syndrome; and Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of genetic neurodevelopmental diseases. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.
OrganisationStoke Therapeutics Inc
Headquarters45 Wiggins Avenue, Bedford, MA, United States, 01730
IndustryBiotechnology
CEOMr. Ian F. Smith A.C.A., C.P.A.
E-voting on sharesClick here to vote

Key Management of Stoke Therapeutics Inc

Name

Title

Doug Snow

Director of Communications & Investor Relations

Dr. Adrian R. Krainer Ph.D.

Co-Founder & Independent Director

Mr. Thomas Edward Leggett

Chief Financial Officer

Dr. Barry S. Ticho FACC, M.D., Ph.D.

Chief Medical Officer

Ms. Isabel Aznarez Ph.D.

Co-Founder, Head of Research & Senior VP

Mr. Jonathan Allan J.D.

Corporate Secretary & General Counsel

Susan Willson

Vice President of Corporate Communications

Ms. Sara Den Besten

Chief People Officer

Mr. Ian F. Smith A.C.A., C.P.A.

CEO & Director

Dr. Edward M. Kaye M.D., Ph.D.

Advisor & Director

FAQs

What is Stoke Therapeutics Inc share price today?

Stoke Therapeutics Inc share price today is $34.93 as on at the close of the market. Stoke Therapeutics Inc share today touched a day high of $37 and a low of $34.64.

What is the 52 week high and 52 week low for Stoke Therapeutics Inc share?

Stoke Therapeutics Inc share touched a 52 week high of $40.22 on and a 52 week low of $8.3 on . Stoke Therapeutics Inc stock price today i.e. is closed at $34.93,which is 13.15% down from its 52 week high and 320.84% up from its 52 week low.

What is Stoke Therapeutics Inc's market capitalisation today?

Stoke Therapeutics Inc market capitalisation is $0.00T as on .

How to invest in Stoke Therapeutics Inc Stock (STOK) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Stoke Therapeutics Inc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Stoke Therapeutics Inc Shares that will get you 0.0429 shares as per Stoke Therapeutics Inc share price of $34.93 per share as on April 24, 2026 at 9:07 am IST.

What is the minimum amount required to buy Stoke Therapeutics Inc Stock (STOK) from India?

Indian investors can start investing in Stoke Therapeutics Inc (STOK) shares with as little as ₹94.085 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹940.85 in Stoke Therapeutics Inc stock (as per the Rupee-Dollar exchange rate as on ). Based on Stoke Therapeutics Inc share’s latest price of $34.93 as on April 24, 2026 at 9:07 am IST, you will get 0.2863 shares of Stoke Therapeutics Inc. Learn more about fractional shares .

What are the returns that Stoke Therapeutics Inc has given to Indian investors in the last 5 years?

Stoke Therapeutics Inc stock has given 13.68% share price returns and 24.28% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?